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ABSTRACT
Objective Oncolytic viruses (OVs) represent promising,
proinﬂammatory cancer treatments. Here, we explored
whether OV-induced innate immune responses could
simultaneously inhibit HCV while suppressing
hepatocellular carcinoma (HCC). Furthermore, we
extended this exemplar to other models of virus-
associated cancer.
Design and results Clinical grade oncolytic
orthoreovirus (Reo) elicited innate immune activation
within primary human liver tissue in the absence of
cytotoxicity and independently of viral genome
replication. As well as achieving therapy in preclinical
models of HCC through the activation of innate
degranulating immune cells, Reo-induced cytokine
responses efﬁciently suppressed HCV replication both in
vitro and in vivo. Furthermore, Reo-induced innate
responses were also effective against models of HBV-
associated HCC, as well as an alternative endogenous
model of Epstein–Barr virus-associated lymphoma.
Interestingly, Reo appeared superior to the majority of
OVs in its ability to elicit innate inﬂammatory responses
from primary liver tissue.
Conclusions We propose that Reo and other select
proinﬂammatory OV may be used in the treatment of
multiple cancers associated with oncogenic virus
infections, simultaneously reducing both virus-associated
oncogenic drive and tumour burden. In the case of HCV-
associated HCC (HCV-HCC), Reo should be considered
as an alternative agent to supplement and support
current HCV-HCC therapies, particularly in those
countries where access to new HCV antiviral treatments
may be limited.
INTRODUCTION
Hepatocellular carcinoma (HCC) is among the
highest causes of cancer-associated mortality and
has limited therapeutic options. The majority of
HCCs are linked with an underlying oncogenic
virus infection, namely HBV (54%) or HCV
(31%).1 HCV-associated HCC (HCV-HCC) has a
particularly high risk of recurrence following surgi-
cal interventions, compared with either HBV-HCC
or other HCC types.2 3 Successful antiviral therapy
prior to hepatic resection and/or liver transplant sig-
niﬁcantly reduces this risk,4 yet toxicity associated
with conventional systemic interferon (IFN)-based
HCV therapy has historically excluded many
newly diagnosed patients with HCV-HCC from
such treatment. New direct-acting antivirals (DAAs)
Signiﬁcance of this study
What is already known on this subject?
▸ The majority of hepatocellular carcinomas
(HCCs) are linked with an underlying oncogenic
virus infection, namely HBV (54%) or HCV
(31%), which drives oncogenesis via both
indirect inﬂammatory and direct carcinogenic
mechanisms. Accordingly, suppression of HBV/
HCV infections may improve HCC clinical
outcomes, but few patients with HCC
worldwide are cured of their hepatitis
infections due to cost, compliance and
treatment toxicity issues.
▸ Therapy for patients with advanced HCC is
limited; Sorafenib only improves median
survival by 2–3 months, is associated with
signiﬁcant side effects and has not been
recommended by the National Institute for
Health and Care Excellence in the UK.
▸ Oncolytic viruses (OVs) show potential as
cancer therapies, killing malignant cells by
direct and immune-mediated mechanisms.
What are the new ﬁndings?
▸ Clinical grade oncolytic orthoreovirus (Reo)
elicited interferon (IFN) secretion and innate
immune activation within primary human liver
tissue in the absence of cytotoxicity and
independently of viral genome replication.
▸ Reo achieved therapy in cell line and murine
models of hepatitis virus-positive/hepatitis
virus-negative HCC and efﬁciently suppressed
HCV replication in vitro through the effects of
repressed replication in vitro, and in vivo,
through the effects of type I IFNs.
▸ The antiviral effects of Reo were also applicable
to in vitro endogenous models of HBV-HCC and
Epstein–Barr virus-associated lymphoma. Of the
other OVs tested, only measles virus
Edmonston strain recapitulated the potent
antiviral effects of Reo.
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with improved safety proﬁles are revolutionising HCV therapy,
yet compliance issues are common,5 and the high cost of DAAs
profoundly limits their use in poorer countries, where the preva-
lence of HCV-HCC is highest.
For patients with advanced HCC, little is known regarding
the impact of antiviral therapy upon existing tumours. Dogma
attributes the emergence and progression of HCV-HCC to a
bystander phenomenon, driven by chronic hepatic inﬂamma-
tion. However, growing evidence indicates that HCV is also
directly oncogenic, further supporting the need for combined
antiviral and anti-tumour therapy. Speciﬁcally, antiviral therapy
improves patient outcomes in HCV-associated lymphoma;6
HCC is more common in HCV-positive livers compared with
autoimmune hepatitis;7 HCV proteins are directly oncogenic in
preclinical models8 and HCV-HCC is more likely to maintain
expression of the tumour suppressor miRNA122, an essential
HCV cofactor, highlighting a critical role for HCV in oncogen-
esis.9 Therapy for patients with advanced HCC is limited;
Sorafenib only improves median survival by 2–3 months, is asso-
ciated with signiﬁcant side effects and has not been recommended
by the National Institute for Health and Care Excellence in the
UK.10–12 Trans-arterial chemotherapy is routinely used for
patients with locally advanced disease/as a bridging therapy to
transplant and has also been tested as a systemic treatment, but is
frequently complicated by reactivation/exacerbation of underlying
HCV/HBV infections.13 14 Thus, given the poor prognosis for
most patients with HCC, a combined antiviral and anti-tumour
therapy might yield signiﬁcant patient beneﬁt.
Oncolytic viruses (OVs) show potential as cancer therapies;
classically, tumour selective killing arises from direct cellular
lysis expedited by virus-associated traits that favour replication
within malignant cells. However, OVs are also potent inducers
of host immunity, which is increasingly recognised to be the
major component of their anti-tumour efﬁcacy.15 Encouraging
responses have been observed in late-stage clinical testing
without signiﬁcant toxicity, with the ﬁrst OV recently licensed
for the treatment of melanoma16 (‘T-Vec’, herpes simplex virus
type 1 (HSV-1) encoding human Granulocyte macrophage
colony stimulating factor (GM-CSF)). The liver and HCC have
been the subject of several OV clinical studies,17 including
JX-594, a modiﬁed vaccinia virus (VV) encoding GM-CSF,18
and our own investigations using oncolytic Orthoreovirus
(Reo) in the treatment of metastatic colorectal cancer (CRC).19
We hypothesised that the proinﬂammatory nature of OV
immunotherapy may exert concomitant beneﬁt upon both the
cancer and the underlying oncogenic virus infection through the
stimulation of innate responses, namely IFNs. Accordingly,
Reo-induced innate immune responses within primary liver
tissue simultaneously effected tumour killing and suppression of
HCV replication in vitro and in vivo. These responses did not
require productive Reo replication and were applicable to other
models of virus-associated tumours. We propose that this dual
mode of action, combined with an excellent safety record, may
favour the rapid deployment of OVs such as Reo for disadvan-
taged patients with advanced, virus-associated HCC.
RESULTS
Reo-induced innate immune responses occur in normal, as
well as cancerous liver
We previously conﬁrmed that Reo efﬁciently targets CRC liver
metastases following intravenous infusion, despite patient neu-
tralising antibodies.19 Cell-mediated virus carriage enabled Reo
replication within tumours and recovery of infectious virus from
tumour explants. However, staining of surrounding normal liver
tissue was also demonstrable in a number of patients, but infec-
tious virus could not be isolated. This led us to re-examine
normal liver patient tissue, conﬁrming Reo protein expression
within 5 out of 10 subjects (ﬁgure 1A).
Next, we examined Reo infection of normal ex vivo human
liver tissue, generating single-cell suspensions. Mixed liver cells
were fractionated into enriched hepatocyte and liver mono-
nuclear cell (LMC) subpopulations (see online supplementary
ﬁgure S1a). Importantly, exposure of enriched primary hepato-
cyte populations to Reo did not cause cellular toxicity (ﬁgure
1B), but did result in limited transcription of viral RNA (ﬁgure
1C) and protein expression 24 hours post-infection (ﬁgure 1D,
E) in the absence of de novo infectious virion production (see
online supplementary ﬁgure S1b). Interestingly, RNA and
protein expression decreased between 24 and 48 hours, suggest-
ive of the induction of cellular antiviral mechanisms (ﬁgure 1D,
E). By contrast, Reo replicated efﬁciently within a broad range
of HCC lines in vitro, producing new infectious virions (see
online supplementary ﬁgure S1c), and inducing cytotoxicity (see
online supplementary ﬁgure S1d), primarily via apoptosis (see
online supplementary ﬁgure S1e). Importantly, potent cytokine
responses were observed upon ex vivo exposure of mixed liver
cells, hepatocyte-enriched or LMC fractions to Reo (ﬁgure 1F).
All cell types expressed IFN-β, whereas IFN-α and IFN-γ segre-
gated primarily within the LMC fraction, and IFN-λ (interleukin
(IL)-28b/IL-29) was more prominent within hepatocyte-enriched
fractions. Thus, Reo has the potential to stimulate innate immun-
ity within a signiﬁcant proportion of the liver, rather than being
restricted to tumour cells and/or tumour-associated LMC.
Reo-induced innate immune responses mediate anti-HCC
therapy
To assess the efﬁcacy of Reo against HCC models with/without
HCV, we employed immunocompromised Severe combined
immunodeﬁciency (SCID) mice bearing subcutaneous Huh7, or
Huh7-JFH1 cell xenografts, carrying a subgenomic HCV repli-
con (genotype 2a, JFH-1 isolate). A single injection of Reo into
palpable tumours (day 5 postimplantation) retarded tumour
growth over a 3–4 week experiment, yielding small, macroscop-
ically less vascular tumours (ﬁgure 2A). Histological examin-
ation of the tumours conﬁrmed expression of HCV
non-structural protein (NS)5A and association of Reo antigen
with necrosis and cleaved caspase 3 (ﬁgure 2B). However,
Reo-treated immunodeﬁcient mice developed considerable tox-
icity evidenced by weight loss (see online supplementary ﬁgure
S2a), necessitating premature sacriﬁce.
To circumvent toxicity issues and to delineate immune-driven,
rather than lytic therapy, we revisited previous studies in
Signiﬁcance of this study
How might it impact on clinical practice in the
foreseeable future?
▸ The deployment of select IFN-focused OVs in patients with
cancer harbouring underlying oncogenic virus infections
either as single agents or in combination therapy is
anticipated to suppress pathogenic infections, improving
organ health and extending cancer-speciﬁc survival.
2 Samson A, et al. Gut 2016;0:1–12. doi:10.1136/gutjnl-2016-312009
Hepatology
Figure 1 Reo reaches normal liver tissue following intravenous injection and stimulates interferon (IFN) secretion from ex vivo liver cells. (A)
Immunohistochemistry (IHC) for Reo σ3 capsid protein (brown) from normal liver tissue derived from a patient treated intravenously with Reo (left)
or an untreated control (right). Slides are representative of the clinical trial series or six untreated controls. (B) Viability assay for enriched ex vivo
hepatocytes treated using Phosphate Buffered Saline (PBS) or 10 PFU/cell Reo for 72 hours and assayed for membrane integrity by Trypan Blue
staining. (C) quantitative reverse transcriptase (qRT)-PCR for Reo σ3. Primary human hepatocytes were treated using 1 PFU/cell Reo or uv-Reo and
incubated for 24 or 48 hours prior to RNA extraction. (D) Western blot for Reo σ3 and β-actin. Primary human hepatocytes were treated using 1
PFU/cell Reo or uv-Reo and incubated for 24 or 48 hours. Mock (M)-treated hepatocytes and RNA puriﬁed from Reolysin stocks (+) served as
negative and positive controls. (E) Human hepatocytes were infected with Reo, or uv-Reo as above, and subjected to immunoﬂuorescence analysis
for Reo σ3 capsid protein, with Hoechst nuclear counterstain. (F) ELISA for IFN-α, IFN-β, interleukin (IL)-28b/IL-29 and IFN-γ derived from ex vivo
mixed liver cells, enriched hepatocytes and liver mononuclear cells (LMCs) following stimulation with Reo or PBS control. * signiﬁes p<0.005.
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Figure 2 Reo-induced innate immune responses are sufﬁcient for anti-hepatocellular carcinoma (HCC) therapy. (A) Excised subcutaneous ﬂank
tumours from SCID mice following a single Itu injection of PBS or 1×106 PFU Reo. (B) Representative IHC staining (brown) for HCV non-structural
protein (NS)5A, Reo σ3 capsid protein and cleaved caspase 3 in Huh7 and Huh7-JFH1 subcutaneous xenografts in SCID mice treated with a single
Itu injection of 1×106 PFU Reo on the 6th day post tumour implantation. (C) Tumour volume of Huh7 (left) and Huh7-JFH1 (right) subcutaneous
ﬂank xenografts in SCID mice treated with 3 times weekly Itu injections of PBS or 1×106 PFU uv-Reo for 4 weeks starting the 6th day post tumour
implantation. (D) ELISA for interferon (IFN)-α, IFN-β, IFN-γ and interleukin (IL)-28b/IL-29 derived from ex vivo mixed liver cells following stimulation
with uv-Reo or PBS control. (E) Tumour growth of 1MEA subcutaneous syngeneic tumours in BALB/c mice treated with 3 times weekly Itu PBS,
1×106 PFU Reo or 1×106 PFU uv-Reo injections, starting the 6th day post tumour implantation. * signiﬁes p<0.005.
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melanoma models, where uv-inactivated Reo (uv-Reo) (see
online supplementary ﬁgure S2b) primed antitumour immune
responses comparably with live virus.20 Accordingly, uv-Reo
caused signiﬁcant retardation of both HCV-positive and
HCV-negative tumour growth (ﬁgure 2C). uv-Reo also elicited
innate cytokine responses from primary human mixed liver cell
suspensions, although this was more focused to IFN-β
(ﬁgure 2D). Finally, an immunocompetent HCC subcutaneous
model (1MEA cells in syngeneic Balb/c mice) revealed similar
reductions in tumour growth for Reo and uv-Reo, supporting
an immune-driven, rather than an oncolytic mechanism of
action (ﬁgure 2E). Taken together, Reo-induced innate immun-
ity appears sufﬁcient for anti-HCC effects in preclinical models,
independent of Reo genomic replication, pointing to a major
role for such a mechanism in humans undergoing treatment
with live clinical grade virus.
Reo-induced anti-HCC responses require IFN-mediated
activation of natural killer lymphocytes
Histological examination of Reo-treated 1MEA tumours revealed
signiﬁcant natural killer (NK) cell inﬁltration, indicating that
these may represent an effector component of the antitumour
response (ﬁgure 3A), as seen for other OVs.21 22 Accordingly,
uv-Reo treatment was ineffective against Huh7 xenografts within
SCID/Beige mice that lack functional immune cell degranulation,
consistent with a therapeutic requirement for NK cell activity
(ﬁgure 3B). Interestingly, increased tumour growth was not
observed in the SCID/Beige compared with the SCID context,
suggesting that degranulating cells could not effectively control
tumour growth in the absence of exogenous stimulation.
Consistent with murine models and our previous data, Reo
effectively stimulated human liver-derived NK cells ex vivo via a
type 1 IFN-dependent mechanism (ﬁgure 3C), thereby activat-
ing a major fraction within the LMC population (see online
supplementary ﬁgure S1a). Likewise, uv-Reo stimulation of
LMC also resulted in NK cell activation (ﬁgure 3D), as did Reo,
also resulting in enhanced killing of both HCV-positive and
HCV-negative Huh7 targets (ﬁgure 3E, F). Moreover, depleting
NK cells from peripheral blood mononuclear cell (PBMC) pre-
vented Reo-stimulated HCC killing (see online supplementary
ﬁgure S3a), further supporting NK cells as major innate effec-
tors in OV-mediated therapy. Thus, Reo-induced anti-HCC
immunity is dependent upon type 1 IFN, which in turn activates
NK cells, enabling them to recognise and kill tumour targets.
Reo-induced immunity exerts potent anti-HCV effects in
vitro
Given the potent induction of inﬂammatory cytokines upon
exposure of ex vivo human liver cells to Reo, we reasoned that
resultant conditioned culture supernatants should exert antiviral
effects. Filtered conditioned media (CM) were prepared follow-
ing control, or Reo (reovirus-CM (RCM)) stimulation of mixed
liver cells, fractionated hepatocyte-enriched and LMC popula-
tions or mixed primary HCC cells. All RCM exerted dose-
dependent inhibitory effects upon HCV replication within
Huh7 cells (ﬁgure 4A). Comparison with puriﬁed, leucocyte-
derived IFN-α, IFN-β or IL-29, or combinations thereof,
revealed a pattern consistent with a primarily IFN-β-mediated
mechanism (see online supplementary ﬁgure S4a); IFN-β was
signiﬁcantly more potent in its ability to inhibit HCV replication
compared with either IFN-α or IL-29, and cytokine combina-
tions did not inhibit HCV replication more than IFN-β alone.
IFN blockade signiﬁcantly attenuated the HCV-inhibitory effect
of mixed liver cell RCM (ﬁgure 4B), with no measurable
cytotoxic or growth-inhibitory effects on Huh7-JFH1 cells (see
online supplementary ﬁgure S4b).
Exposure of multiple HCC lines to Reo resulted in variable pat-
terns of cytokine induction, lacking IFN-α, but with signiﬁcant
amounts of IFN-β and IFN-λ (ﬁgure 4C). We deﬁned RCM
derived from stimulated JHH1, HLE and JHH2 cells as retaining
high, medium and low IFN-β content, respectively. Antiviral effects
directly correlated with RCM IFN-β levels, mirroring the trend line
equation for puriﬁed leukocyte-derived cytokine (Spearman’s rank
correlation of 0.929, p=0.001) (ﬁgure 4D, see online
supplementary ﬁgure S4a). Concomitant decline in HCV protein
expression was observed by both immunoﬂuorescence (ﬁgure 4E)
and western blot (see online supplementary ﬁgure S4c), again with
no discernible cytotoxic effects (see online supplementary ﬁgure
S4d). Critically, RCM antiviral activity was also applicable to full-
length infectious HCV, again with direct correlation to IFN-β
levels, measured by reductions in NS5A-luciferase reporter activity
(ﬁgure 4F, see online supplementary ﬁgure S4e), HCV genomic
RNA (see online supplementary ﬁgure S5a) and NS5A-Green
Fluorescent Protein (GFP) reporter gene ﬂuorescence (see online
supplementary ﬁgure S5b, c).
Reo-induced immunity eradicates HCV from cell culture and
exerts antiviral effects in vivo
We next examined whether RCM exposure could effectively
cure Huh7-JFH-1 cells. Huh7-JFH-1 were exposed to RCM or
control media for 14 days in the absence of selection.
Rechallenge with G418 led to a lack of viable colonies in JHH1
RCM or IFN-β-treated cells, with undetectable luciferase activ-
ity in bulk populations (ﬁgure 5A).
Next, we tested whether uv-Reo-stimulated immunity could
exert an antiviral effect in the preclinical SCID Huh7-JFH-1
model. Palpable subcutaneous Huh7-JFH-1 xenografts were
treated intratumourally with either low-dose uv-Reo or PBS
over a 9-day period, measuring tumour growth, as well as HCV
expressed luciferase within tumours using an in vivo imaging
system (IVIS). Tumours were normalised and segregated into
equivalent control/treatment groups based upon IVIS readings at
day 0. While luciferase readings naturally declined in controls
due to the lack of G418, treatment with low-dose uv-Reo led to
a signiﬁcant additional reduction in IVIS readings, independent
of tumour growth (ﬁgure 5B, C). Furthermore, histological
examination of additional Huh7-JFH-1 tumours treated with a
single injection of live Reo revealed marked reductions in HCV
NS5A protein expression in areas of the tumour distinct from
those undergoing necrotic changes or staining for Reo antigen,
supportive of a trans-acting, cytokine-mediated antiviral effect
(see online supplementary ﬁgure S6a). Accordingly, RCM gener-
ated from uv-Reo exposure of mixed murine liver cells retained
anti-HCV activity in HUH7-JFH1 cells (see online
supplementary ﬁgure S6b), albeit signiﬁcantly reduced com-
pared with human RCM. Hence, while murine RCM/IFN par-
tially cross-stimulates Huh7 IFN receptors, murine xenograft
models likely underestimate the magnitude of inhibition poten-
tially achievable within a human context.
Reo-induced antiviral responses are achievable in other
models of virus-associated cancer
We reasoned that similar antiviral efﬁcacy may be achieved in
other models of virus-associated cancer. We assessed the effects
of Reo-stimulated immunity against PLC/PRF/5 cells containing
integrated HBV, and Daudi cells, which are derived from an
Epstein–Barr virus (EBV)-positive Burkitt’s lymphoma, known
to be resistant to Reo-induced cytotoxic effects.23
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PLC/PRF/5 HBV surface antigen (HBsAg) secretion serves as
a marker of viral gene expression.24 RCM derived from both
primary LMC and also JHH-1 cells achieved reductions of
HBsAg secretion comparable with puriﬁed IFN-β over a 5-day
time course (ﬁgure 6A, see online supplementary ﬁgure S7a),
with no observable growth-inhibitory effects (see online
supplementary ﬁgure S7b). We next tested the ability of Reo to
suppress EBV reactivation from tetradecanoylphorbol-13-acetate
(TPA)/butyrate-treated Daudi cells. Both direct Reo treatment of
Daudi cells and exposure to RCM derived from PBMC led to a
signiﬁcant reduction of EBV early antigen (EA)-positive cells
(ﬁgure 6B, C). As Daudi cells are not permissive hosts, this
effect was likely attributable to Reo-induced cytokines.
Finally, we assessed whether Reo was unique in its ability to
generate potent anti-HCV cytokine responses from human
primary mixed liver cells. From a panel of commonly researched
OVs, only CM generated by exposure to measles virus
Edmonston strain (MV-Edm) recapitulated the anti-HCV efﬁ-
cacy seen for Reo against Huh7-JFH-1 cells (ﬁgure 6D).
Exposure to very high concentrations of HSV-1 CM generated
only modest effects, whereas VV did not elicit appreciable anti-
viral responses. Moreover, correlation between antiviral effects
and those predicted to be attributable to the induction of IFN-β
(see online supplementary ﬁgure S7c) was signiﬁcant (p<0.05)
for all OVs except VV; low levels of cytokine were present in
VV CM at similar concentrations to that released from mock-
Figure 3 Reo-stimulated interferon (IFN) drives anti-hepatocellular carcinoma (HCC) immune responses via natural killer (NK) cell activation. (A)
Representative IHC staining (brown) for NK cells in 1MEA subcutaneous syngeneic tumours in BALB/c mice treated with 3 times weekly Itu injections
of PBS or 1×106 PFU Reo. (B) Tumour growth of Huh7 subcutaneous xenografts in SCID/Beige mice treated with 3 times weekly Itu injections of PBS
or 1×106 PFU uv-Reo. (C) Flow cytometry overlay plot (left) and quantiﬁcation (right) of median ﬂuorescence intensity (MFI) for NK CD69 expression
within liver mononuclear cells (LMCs) treated using PBS, 1 PFU/cell Reo, 1 PFU/cell Reo and type I IFN blocking antibodies or 1 PFU/cell Reo and
isotype antibodies. (D) Similar to (C), but LMCs were treated with PBS, 1 PFU/cell Reo or 1 PFU/cell uv-Reo. (E) Degranulation assay showing per
cent CD107-positive liver NK cells. LMCs were pretreated with PBS or 1 PFU/cell Reo for 24 hours, then coincubated with Huh7 or Huh7-JFH1
targets for 4 hours. (F) 51Cr release assay using LMCs pretreated with PBS or 1 PFU/cell Reo for 24 hours, then washed and coincubated with
51Cr-labelled Huh7 or Huh7-JFH1 targets for 4 hours. Data are 51Cr release as a percentage of the potential maximum. *signiﬁes p<0.005.
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treated hepatic cells, yet neither exerted antiviral effects upon
Huh7-JFH-1 cells. Hence, other factors present in control
media may ameliorate the effects of low-level IFN or these low
levels may not tally with the predictive equation (see online
supplementary ﬁgure S7c). Taken together, Reo appears capable
of inducing potent, IFN-β-driven antiviral responses that are
effective against both RNA and DNA tumour viruses, yet this
ability is not ubiquitous among OVs.
Figure 4 Reo-stimulated interferon (IFN)-β potently inhibits HCV in vitro. (A) Luciferase assay using Huh7-JFH1 cells treated for 24 hours with a
range of dilutions of conditioned media (CM) or reovirus-CM (RCM) derived from mixed liver cells, liver mononuclear cells (LMCs), enriched
hepatocytes or mixed primary hepatocellular carcinoma (HCC) cells. Luciferase activity was calculated as a percentage of control media values. (B)
Luciferase assay using Huh7-JFH1 cells treated for 4 hours with mixed liver cell RCM (1:16 dilution), mixed liver cell RCM and type I IFN blocking
antibodies or mixed liver cell RCM and isotype antibodies. Cells were then incubated in full growth media without treatment for a further 20 hours
prior to analysis. (C) ELISA for IFN-β (left) and interleukin (IL)-28b/IL-29 (right) secretion from a panel of HCC cell lines following treatment for
72 hours with PBS or 1 PFU/cell Reo. (D) Luciferase assay using Huh7-JFH1 cells treated for 24 hours with a range of dilutions of CM or RCM
derived from JHH1, HLE or JHH2 cells. Dotted red lines represent predicted per cent luciferase activity as a function of RCM IFN-β concentrations, as
predicted from the trend line equation for replicon inhibition using puriﬁed IFN-β (see online supplementary ﬁgure 4SA). (E) Representative
immunoﬂuorescence for HCV non-structural protein (NS)5A in Huh7-JFH1 cells treated for 24 hours with CM or RCM at a dilution of 1:16 derived
from JHH1, HLE or JHH2 cells. (F) Luciferase assays using HCV-infected Huh7 cells, treated for 24 hours with CM or RCM derived from JHH1, HLE or
JHH2 cells at a dilution of 1:16. * signiﬁes p<0.005.
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DISCUSSION
Here, we have provided the ﬁrst evidence that OV-induced
innate inﬂammatory responses simultaneously target onco-
genic virus infections as well as associated tumours using
primarily the exemplar of HCV-HCC, but with additional
proof-of-principle for other models. Induction of type I IFN
was a key, unifying mechanism determining both antiviral
as well as anti-tumour efﬁcacy in our model systems, and efﬁ-
cacy achieved using uv-Reo argues against a signiﬁcant role
for direct tumour targeting/lysis. Moreover, such qualities
Figure 5 Reo-induced inﬂammatory
responses eradicate HCV from cell
culture and exert antiviral effects in
vivo. (A) Huh7-JFH1 cells were treated
for 14 days with reovirus-CM (RCM) or
conditioned media (CM) derived from
JHH1 cells at a dilution of 1:16, or
with control media, or puriﬁed
interferon (IFN)-β at 50 pg/mL. Cells
were then either quantiﬁed for
luciferase activity (bottom right) or
seeded at the densities shown in top
right and cultured in media containing
G418 for 4 days before ﬁxation and
staining in methylene blue (left). (B)
Representative in vivo imaging system
(IVIS) pictures of HCV replicon
luciferase activity within subcutaneous
Huh7-JFH1 xenografts in SCID mice.
Mice were treated with twice weekly
Itu injections of PBS or 1×105 PFU uv-
Reo, starting immediately following
baseline assessment. (C) (Left)
Quantiﬁcation of IVIS luciferase
intensity from (B). Graph shows per
cent luciferase activity in relation to
day 0 post-treatment baseline values.
(Right) Tumour volume of xenografts
shown in (B).
8 Samson A, et al. Gut 2016;0:1–12. doi:10.1136/gutjnl-2016-312009
Hepatology
were not ubiquitous among OVs, making the selection of
agent for future applications an important consideration.
Reo-induced IFN both exerted direct antiviral effects upon
virus replication in vitro and anti-tumour effects in vivo via acti-
vation of degranulating innate immune cells, most likely NK
cells. Hence, SCID/beige mice were unable to respond to
uv-Reo therapy, yet this was not compromised by the lack of
adaptive immunity within the SCID background. NK cells are
indirectly activated by IFN,25 and they likely also contribute to
in vivo antiviral effects via the killing of infected tumour cells/
hepatocytes.26
IFN-β-mediated antiviral and anti-tumour effects in preclinical
models were not dependent upon Reo replication, as uv-Reo
primed similar responses from human hepatic cells. This is rem-
iniscent of other OV studies, where the ability to complete a full
infectious cycle is dispensable for the priming of IFN-mediated
Figure 6 Reo-induced antiviral responses inhibit HBV and Epstein–Barr virus (EBV) in vitro. (A) ELISA for HBV surface antigen (HBsAg) secreted from
PLC/PRF/5 cells treated for 5 days using a range of dilutions of conditioned media (CM) or reovirus-CM (RCM) derived from liver mononuclear cell
(LMCs) (top) or JHH1 (bottom) cells. (B) Representative immunoﬂuorescence (left) for EBV early antigen (EA) and quantiﬁcation of EA-positive (right)
Daudi cells. Cells were treated using PBS for 48 hours, 1 PFU/cell Reo for 48 hours, Histone deacetylase inhibitor (HDI) for 24 hours or 1 PFU/cell Reo
for 48 hours followed by HDI for 24 hours. (C) (Left) ELISA for interferon (IFN)-α, IFN-β, IFN-γ and interleukin (IL)-28b/IL-29 derived from peripheral
blood MC (PBMC) following stimulation with Reo or PBS control. (Right) Quantiﬁcation of EA-positive Daudi cells treated for 24 hours using control
media, PBMC CM, PBMC RCM, all followed by a further 24 hours treatment using either PBS or HDI. (D) Luciferase assay using Huh7-JFH1 cells treated
for 24 hours with a range of dilutions of CM or 10 PFU/cell oncolytic virus (OV)-CM derived from mixed liver cells. * signiﬁes p<0.005.
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anti-tumour immunity.20 22 27 Nevertheless, it is likely that
replication-competent virus provides other clinical advantages
when treating preimmune human patients, such as potential amp-
liﬁcation at tumour sites,19 and cell-mediated carriage28 to miti-
gate existing antibody responses; whether the latter occurs for
uv-inactivated virus is unknown, and this would currently be
impossible to test in vivo given the absence of clinical grade
reagent. dsRNA human Orthoreovirus genomes are recognised
by pattern recognition receptors, including RIG-I,29 although
whether this is also true for uv-Reo is unclear. Other reoviruses,
such as Carp reovirus, are also known to trigger responses
through Toll-like-receptor pathways,30 yet the extent to which
these are activated by uv-Reo in human liver cells is unknown.
We cannot rule out a contribution of adaptive immunity to
therapy in syngeneic 1MEA models, but this would likely be in
addition to the essential innate anti-tumour response.
This study provides a novel antiviral dimension to
OV-induced innate responses, which in turn also mediate much
of their anti-tumour efﬁcacy. This could have signiﬁcant beneﬁt
for cancers such as HCC, for which therapeutic options are
limited and the majority occur as a result of either HBV or
HCV infection. Preclinical models available for the study of
HCV or indeed HBV infection/replication remain severely
limited, and all are set within altered genetic or induced
immunocompromised backgrounds.31 32 Furthermore, trans-
genic murine systems that spontaneously develop HCC in an
HCV context necessarily express viral proteins under autolo-
gous promoters rather than in a replicative context, making
these unsuitable for testing OV-mediated therapy. The
Huh7-JFH1 xenograft models employed in the present study
are also limited, but provide the advantage of replicating HCV
within an HCC context, where responses to innate immune sig-
nalling remain intact.
New DAAs targeting HCV have recently been shown to be
well tolerated in patients with HCV-HCC.33 Interestingly, sus-
tained DAA responses in patients with chronic HCV were
recently shown to correlate with restoration of hepatic type I
IFN signalling homeostasis and increased expression of a
deﬁned series of IFN-stimulated genes (ISGs) upon the cessation
of treatment.34 OV treatment combined with DAAs could con-
ceivably improve the rate at which such intrahepatic ISG expres-
sion takes place, effectively improving viral clearance in patients
with HCC. However, the likelihood is that the majority of
patients with access to DAAs will have their HCV infection
cured prior to the development of HCC, and the accumulating
evidence that HCV is directly oncogenic provides a strong
rationale to adopt the same practice for patients with advanced
HCC. Thus, Reo could have particular relevance in countries
unable to support widespread administration of DAAs, where
both HCV and so also HCC prevalence may be higher.
Furthermore, Reo anti-HCC effects could conceivably support
or serve as second-line therapy to Sorafenib standard of care or
form combinations with trans-arterial chemotherapy. This may
become increasingly relevant in light of recent controversial
studies supporting that DAA therapy may not be as effective as
IFN in preventing the recurrence of HCV-HCC following
surgery, although this awaits conﬁrmation in much larger
patient cohorts.35 36
We have previously demonstrated that Reo-induced immunity
is applicable to a number of varied tumour scenarios, and here
we show that this innate immune activation displays antiviral
efﬁcacy. However, this trait was not common to all other OVs
tested, with only MV-Edm sharing the ability of Reo to strongly
induce type I IFN expression within primary human hepatic
cells. Perhaps unsurprisingly, this suggests that OVs hailing from
different virus families may vary in the principal mechanism by
which they exert anti-tumour effects. Interestingly, VV, the plat-
form for the modiﬁed JX-594, was a poor activator of innate
responses within primary hepatic tissue; it is possible that the
considerable array of innate immune antagonists encoded by VV
contribute to this outcome.37 Interestingly, JX-594 therapy
reduced HBV loads in a small cohort of patients with HCC in a
trial substudy, yet this was not directly attributed to hepatic
immune stimulation.38
The clinical potential for Reo to act as a combined antiviral
and anti-tumour therapy in the context of HCV-HCC is sup-
ported by our ﬁnding that the virus can access normal liver
tissue as well as tumours, following intravenous delivery in
patients. Accordingly, exposure of ex vivo primary hepatic cells
to Reo resulted in both viral RNA transcription and protein
expression, although this did not culminate in the secretion of
de novo infectious particles. This correlated with potent IFN
induction within normal human liver cells in the absence of
overt toxicity; hence, we infer that such responses limit, rather
than prevent, viral replication within normal in vivo tissue,
whereas this is less likely to occur in a tumour context, thereby
subtly modifying the classical model for OV tumour speciﬁcity.
As such, the favourable safety proﬁle of Reo is well suited to the
advanced hepatic disease state in patients with HCC, the major-
ity of whom have underlying cirrhosis. Encouragingly, HCC
biopsies from patients injected with OV in clinical trials showed
diffuse lymphocyte inﬁltration,18 further supporting the use of
OVs as combined antiviral and anti-HCC immunotherapies.
Based upon their excellent safety records, we propose that the
deployment of select OVs in patients with cancer harbouring
underlying oncogenic virus infections be explored in clinical
trials. Future research should combine IFN-focused OV such as
Reo with other immunostimulatory agents, including immune
checkpoint inhibitors (CI). Interestingly, the converse applica-
tion of CI as antivirals is being explored for chronic infections
such as HIV,39 suggesting that both Reo-like OVs and CI may
form effective antiviral/anti-tumour combination therapies.
MATERIALS AND METHODS
Ethical standards
Ex vivo normal and malignant liver tissues were obtained from
patients undergoing routine planned cancer-related surgery at
St. James’ University Hospital, Leeds, UK. Written informed
consent was obtained in accordance with local institutional
ethics review and approval.
Immunohistochemistry
Employed an automated Bond Max system (Leica Biosystems) as
described.40 Reovirus σ3 and cleaved caspase 3 antibodies were
diluted to 1:1000. Detection of HCV NS5A included antigen
retrieval and antibody dilution of 1:100. CD117 represented an
NK cell-speciﬁc marker.41
Fluorescence microscopy
Sheep anti-NS5A polyclonal serum (1:2000, from Mark Harris,
Leeds),42 mouse anti-EBV EA-D clone (0261) (Santa Cruz,
1:100), Alexa Fluor-conjugated secondary antibodies
(Invitrogen, 1:200) or direct GFP ﬂuorescence was imaged
using an EVOS FL Cell Imaging System or an Incuyte Zoom.
4F2 (reovirus σ3 antibody) was deposited to the DSHB by
Dermody, T.S. (DSHB Hybridoma Product 4F2 (reovirus)).
Huh7-JFH1 cells were treated with CM or RCM diluted 1:16
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for 24 hours. Daudi cells were treated with 20 ng/mL TPA and
3 mM sodium butyrate.
Preparation and quantiﬁcation of HCV RNA
Total RNA was extracted from Huh7 cells containing HCV
using TRIzol Reagent (Ambion), following the manufacturer’s
protocol. Reverse transcription was undertaken using a
SensiFAST cDNA Synthesis Kit (Bioline). Quantiﬁcation of
HCV transcripts was undertaken using SYBR Green Real-Time
PCR Master Mix (Applied Biosystems) on an Applied
Biosystems 7500 Fast Real-Time PCR System, using standard
conditions, with an annealing temperature of 63°C. The primer
sequences were speciﬁc to the HCV 50 UTR; Fwd,
50-agcgtctagccatggcgt-30 and Rev, 50-ggtgtactcaccggttccg-30,
resulting in a 95 bp amplicon.
Generation of (virus-)CM
CM and virus-CM (RCM) were derived from mixed liver cells
or enriched hepatocytes treated with oncolytic reovirus,
MV-Edm, VV or HSV-1 at 10 PFU/cell, or PBS, for 72 hours.
Hepatoma lines, LMCs and PBMCs were treated with Reo at 1
PFU/cell for 72 hours. Supernatants were clariﬁed at 400 ×g for
5 min, then ﬁltered twice (2 mm (Corning) followed by
OptiScale 25 Capsule (Millipore) to remove residual virus) and
stored at −80°C.
Type I IFN blockade
Huh7-JFH1 cells were treated with 1.25% (v/v) antihuman
IFN-α/β receptor chain 2 or 1.25% (v/v) IgG2a isotype, R&D
systems, and RCM is mixed with 0.75% (v/v) antihuman IFN-α
and 0.75% (v/v) antihuman IFN-β, R&D systems or 1.5% (v/v)
heat-inactivated sheep serum control, Sigma and incubated sep-
arately for 1 hour prior to mixing. After 4 hours, media was
replaced without treatment. MTT/luciferase assays were con-
ducted after a further 20 hours. LMCs were treated 1 hour
prior to Reo stimulation and incubated for 24 hours prior to
ﬂow cytometry.
Trypan Blue exclusion
Primary enriched hepatocytes were treated with PBS or
10 PFU/cell Reo for 72 hours, diluted 1:1 with 0.4% Trypan
Blue (Sigma) and viability was determined from three replicates
of 200 counted cells.
Flow cytometry
Flow cytometry was performed using a BD LSRII ﬂow cyt-
ometer and data were analysed on FACSDiva software (BD
Biosciences). All antibodies comprised ﬂuorescent-conjugated
mouse monoclonal IgG1.
Liver NK cell CD69: washed LMCs were labelled with
Fluorescein isothiocyanate (FITC)-CD56, PerCP-CD3 and
PE-CD69 IgG1 antibodies (all BD Biosciences). Controls were
labelled with PE-conjugated IgG1 isotype.
CD107 a/b degranulation: LMCs were incubated for 24 hours
with 1 PFU/cell reovirus or PBS, washed twice in Hanks'
Balanced Salt Solution (HBSS) (Sigma) and coincubated with
target cells at a ratio of 5:1 for 4 hours. At 1 hour, cells were
labelled with FITC-CD107a, FITC-CD107b antibodies (BD
Biosciences), PE-CD56 (AbD Serotec) and PerCP-CD3 (BD
Biosciences), with Brefeldin A solution (Biolegend).
ELISA
IFN-α (Mabtech), IFN-β (Verikine Human IFN Beta ELISA Kit
(PBL)), IFN-γ (BD Biosciences) and IL-28b/IL-29 (R&D
Systems) were detected using matched HBsAg antibody pairs.
PLC/PRF/5 cells were RCM treated for 5 days with daily
replacement, followed by a ﬁnal 3 hours treatment assessed for
HBsAg using the Monolisa HBsAg ULTRA Kit (Bio-Rad), as per
manufacturer instructions.
Luciferase assay
Fireﬂy (subgenomic HCV) or Renilla (infectious HCV)
Luciferase assay systems (Promega) were assessed according to
manufacturer’s protocols using a MITHRAS luminometer
(Berthold Technologie).
51Chromium release assay
51Chromium release was measured as described.43 Effector
cells (LMCs or PBMCs) were preincubated for 24 hours with
1 PFU/cell of reovirus or PBS and dispensed in triplicate at the
stated effector to target ratios.
In vivo experiments
CB17-PrkdcSCID (SCID) mice were provided by the St. James’
Biomedical Service (SBS). BALB/c mice and CB17 (PrkdcSCID,
Lystbg ‘SCID/Beige’) were purchased from Charles River
Laboratories International. SCID and SCID/Beige mice were
housed in isolator cages, while BALB/c mice were housed in indi-
vidually ventilated cages. Cell lines were conﬁrmed free of
murine pathogens (Charles River Laboratories). Mice were regu-
larly examined for signs of deterioration in health or weight loss.
Cell lines were harvested, washed twice in PBS and resus-
pended in 100 mL PBS for subcutaneous injection. All treat-
ments were in 50 mL of vehicle ﬂuid (PBS for Reo/uv-Reo or for
Sorafenib by oral gavage in vehicle; PBS, 25% polyethylene
glycol 400 (Sigma), 5% Tween-20, 5% ethanol).
Tumour growth was measured in two dimensions using calli-
pers and mice were routinely sacriﬁced when 15 mm was
reached in any dimension. Tumour volumes were calculated
according to the modiﬁed ellipsoidal formula.44
For the IVIS (Caliper Life Sciences), SCID mice were anaesthe-
tised by 1.5% isoﬂuorane inhalation and injected intraperitone-
ally with 80 mL of 150 mg/mL Fireﬂy D-luciferin potassium salt
(Caliper Life Sciences) dissolved in PBS. Luciferase activity was
measured after 10 min. Data were analysed using Living Image
Software for IVIS (Perkin Elmer) by quantifying the total emitted
luminescence within a circular area corresponding to the tumour
injection site and subtracting the background emission.
Statistics
p Values were calculated by the two-sided paired t-test for single
points or groups, and statistical signiﬁcance is denoted by
*p<0.05. Cells or supernatants were assayed in triplicate when
possible and data represent the mean and SEM between repeat
experiments or samples from different donors.
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